Comparison efficacy of different regimens of insulin therapy in patients with type 2 diabetes and morbid obesity

Abstract

Introduction. In type 2 diabetes mellitus, an inevitable decrease in the secretion of β-cells of the pancreas occurs, which requires the initiation of insulin therapy. Currently, there have been no studies evaluating the features of insulin therapy in patients with diabetes type 2 and morbid obesity.Objective. To compare the effectiveness of different insulin therapy regimens in patients with type 2 diabetes mellitus and morbid obesity. Materials and methods. 140 patients with diabetes type 2 and morbid obesity were included in a 24-week prospective, non-blinded, randomized clinical study. The patients were divided into 4 groups: 1 – received basic-bolus insulin therapy in combination with metformin (n = 40); 2 – used prandial insulin in combination with metformin (n = 40); 3 – basal insulin in combination with empagliflozin and metformin (n = 30); 4 – received prandial insulin in combination with empagliflozin and metformin (n = 30). Initially, after 12 and 24 weeks, the level of HbA1c, fasting plasma glucose and during the day, body weight, daily insulin doses, frequency of hypoglycemia, and albumin in daily urine were assessed.Results. After 24 weeks of treatment, there was no statistically significant difference in the achieved HbA1c level between the groups (p = 0.65); in groups 3 and 4, there was a statistically significant decrease in body weight, daily doses of insulin and frequency of hypoglycemia compared to the first and second treatment groups (p = 0.029, p < 0.001 and p < 0,001, respectively); also registered a decrease in albumin in daily urine by 27% during the study period compared with the first and second treatment groups (p = 0.044).Conclusions. Administration of iSGLT-2 in combination with both basal and prandial insulin in patients with diabetes type 2 and morbid obesity has advantages over the basic-bolus regimen and the regimen of multiple prandial injections, despite the comparable efficacy.

Keywords

• type 2 diabetes mellitus
• morbid obesity
• insulin therapy
• isglt-2
• prandial insulin